Literature DB >> 17601491

PPARalpha is a key regulator of hepatic FGF21.

Thomas Lundåsen1, Mary C Hunt, Lisa-Mari Nilsson, Sabyasachi Sanyal, Bo Angelin, Stefan E H Alexson, Mats Rudling.   

Abstract

The metabolic regulator fibroblast growth factor 21 (FGF21) has antidiabetic properties in animal models of diabetes and obesity. Using quantitative RT-PCR, we here show that the hepatic gene expression of FGF21 is regulated by the peroxisome proliferator-activated receptor alpha (PPARalpha). Fasting or treatment of mice with the PPARalpha agonist Wy-14,643 induced FGF21 mRNA by 10-fold and 8-fold, respectively. In contrast, FGF21 mRNA was low in PPARalpha deficient mice, and fasting or treatment with Wy-14,643 did not induce FGF21. Obese ob/ob mice, known to have increased PPARalpha levels, displayed 12-fold increased hepatic FGF21 mRNA levels. The potential importance of PPARalpha for FGF21 expression also in human liver was shown by Wy-14,643 induction of FGF21 mRNA in human primary hepatocytes, and PPARalpha response elements were identified in both the human and mouse FGF21 promoters. Further studies on the mechanisms of regulation of FGF21 by PPARalpha in humans will be of great interest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17601491     DOI: 10.1016/j.bbrc.2007.06.068

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  155 in total

1.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

2.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

Review 3.  Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

Authors:  Matthew J Potthoff; Steven A Kliewer; David J Mangelsdorf
Journal:  Genes Dev       Date:  2012-02-02       Impact factor: 11.361

Review 4.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

5.  Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alpha.

Authors:  Yongjun Wang; Laura A Solt; Thomas P Burris
Journal:  J Biol Chem       Date:  2010-03-23       Impact factor: 5.157

6.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

Authors:  Wei Wei; Paul A Dutchak; Xunde Wang; Xunshan Ding; Xueqian Wang; Angie L Bookout; Regina Goetz; Moosa Mohammadi; Robert D Gerard; Paul C Dechow; David J Mangelsdorf; Steven A Kliewer; Yihong Wan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

7.  Sequential changes in the expression of genes involved in lipid metabolism in adipose tissue and liver in response to fasting.

Authors:  M Palou; T Priego; J Sánchez; E Villegas; A M Rodríguez; A Palou; C Picó
Journal:  Pflugers Arch       Date:  2008-05-21       Impact factor: 3.657

8.  Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Authors:  Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2013-05-29       Impact factor: 7.422

Review 9.  Fibroblast growth factor 21: from pharmacology to physiology.

Authors:  Steven A Kliewer; David J Mangelsdorf
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

10.  Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice.

Authors:  Xi Wu; Yong-Fen Qi; Jin-Rui Chang; Wei-Wei Lu; Jin-Sheng Zhang; Shao-Ping Wang; Shu-Juan Cheng; Ming Zhang; Qian Fan; Yuan Lv; Hui Zhu; Man-Kun Xin; Yun Lv; Jing-Hua Liu
Journal:  Heart Vessels       Date:  2014-08-05       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.